NASDAQ · TRDA
Healthcare · Biotechnology
$7.57
Down-$0.03 (-0.39%)
Updated Aug 23, 2026, 2:28 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TRDA closed at $7.57 after 20 trading sessions, up 24.51% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $7.64 | $7.735 | $7.44 | $7.57 | 141.02K |
| Aug 20, 2026 | $7.76 | $7.765 | $7.30 | $7.60 | 250.04K |
| Aug 19, 2026 | $7.49 | $7.79 | $7.395 | $7.78 | 241.84K |
| Aug 18, 2026 | $7.21 | $7.43 | $7.16 | $7.27 | 129.76K |
| Aug 17, 2026 | $7.33 | $7.56 | $7.25 | $7.32 | 193.11K |
| Aug 14, 2026 | $7.45 | $7.53 | $7.21 | $7.46 | 237.99K |
| Aug 13, 2026 | $7.74 | $7.765 | $7.369 | $7.45 | 236.44K |
| Aug 12, 2026 | $7.03 | $7.68 | $6.93 | $7.67 | 263.66K |
| Aug 11, 2026 | $7.00 | $7.27 | $6.93 | $7.04 | 264.1K |
| Aug 10, 2026 | $6.87 | $7.26 | $6.83 | $6.95 | 411.84K |
| Aug 7, 2026 | $6.94 | $7.085 | $6.75 | $6.87 | 458.07K |
| Aug 6, 2026 | $7.05 | $7.11 | $6.74 | $6.87 | 269.97K |
| Aug 5, 2026 | $7.47 | $7.47 | $6.85 | $7.06 | 591.55K |
| Aug 4, 2026 | $6.945 | $7.97 | $6.945 | $7.24 | 663.13K |
| Aug 3, 2026 | $6.83 | $7.31 | $6.64 | $7.26 | 500.5K |
| Jul 31, 2026 | $6.71 | $6.90 | $6.49 | $6.79 | 352.6K |
| Jul 30, 2026 | $6.55 | $7.04 | $6.45 | $6.77 | 594.75K |
| Jul 29, 2026 | $5.78 | $6.73 | $5.78 | $6.55 | 435.42K |
| Jul 28, 2026 | $6.10 | $6.11 | $5.72 | $5.83 | 445.75K |
| Jul 27, 2026 | $5.95 | $6.23 | $5.95 | $6.08 | 446.76K |
The latest Smart Investors Daily articles mentioning TRDA.
TRDA research
Company profile and research snapshot.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | Guggenheim | Buy | — |
| May 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Apr 6, 2026 | Oppenheimer | Outperform | — |
| Feb 18, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 5, 2026
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Aug 5, 2026
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc
Benzinga · Aug 5, 2026
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.09) by 7.34 percent. This is a 2.88 percent increase over losses of $(1.04) per share
Yahoo · Aug 3, 2026
Compugen (CGEN) delivered earnings and revenue surprises of 0.00% and -3.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TRDA.
